Resolute System    

Log In
 
 

Forgot Your Password?
 


Not a member? Click here!

Evolving Utility of Aspirin and Thienopyridines: New Insights Into Anti-Platelet Resistance
New Antiplatelet Agents
New Strategies and Devices to Manage Cardiogenic Shock
Will Cangrelor Replace Clopidogrel and IIb IIIa Inhibitors in the Lab
Will the New Antiplatelet Agents in the Pipeline Replace Clopidogrel?






 

 

More Support for Radial Access PCI

Radial access PCI may be associated with reduced access site bleeding complications. Analysis of data from the British Cardiovascular Intervention Society database has indicated that radial access PCI may be associated with reduced 30-day mortality and that the magnitude of this effect is related to the baseline bleeding risk.

For more, click here

 

 

 

Impact of Drug-Eluting Balloons in the Periphery

Drug eluting balloons (DEB) may be associated with reduced risk of in-stent restenosis. The IN.PACT study, a randomized trial of conventional balloon angioplasty versus DEB in patients with critical limb ischemia, has shown no benefit of DEB with regards to late lumen loss or TLR.

For more, click here

 

 

 

Novel Genetic Advances in AF

The genetic basis of AF has not been clearly elucidated. Using a multifaceted approach from European and Japanese individuals, 5 novel loci for AF have been identified that could serve as molecular targets for pharmacological investigations.

For more, click here

 

 

 

Persistent Benefits of BP Control in Type II DM

The ADVANCE trial had indicated that BP lowering with perindopril and indapamide reduced mortality in patients with type II DM. Results from the 6-year post-trial follow-up has indicated that this benefit has persisted. No benefit was observed in terms of mortality or macrovascular events with intensive glucose control as had been observed in the original trial.

For more, click here

 

<
||
>































CRT2013
Untitled Document
 
Minimizing Femoral Artery Access Complications during PCI
- Michael S. Lee, MD
PROTECT Trial: 5 Year Outcomes
- Edoardo Camenzind, MD
Reduction in office blood pressure after renal denervation in a large real world patient population with uncontrolled hypertension: interim 12-month results from the Global SYMPLICITY Registry
- Felix Mahfoud, MD
SYMPLICITY HTN-3 Trial: 12-month outcomes following un-blinding of subjects at 6 months
- George L. Bakris, MD



Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD

 Click here to visit the WEBEX archives


Baseline Bleeding Risk and Arterial Access Site Practice in Relation to Procedural Outcomes After Percutaneous Coronary Intervention.
M Mamas, et al.
JACC 2014; 64:1554-1564
Drug-Eluting Balloon Versus Standard Balloon Angioplasty for Infrapopliteal Arterial Revascularization in Critical Limb Ischemia: 12-Month Results From the IN.PACT DEEP Randomized Trial.
T Zeller, et al.
JACC 2014; 64:1568-1576
Impact of Long-Term Burden of Excessive Adiposity and Elevated Blood Pressure From Childhood on Adulthood Left Ventricular Remodeling Patterns: The Bogalusa Heart Study.
C Lai, et al.
JACC 2014; 64:1580-1587
Follow-Up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes.
S Zoungas, et al.
NEJM 2014; 371:1392-1406
Integrating Genetic, Transcriptional, and Functional Analyses to Identify 5 Novel Genes for Atrial Fibrillation.
M Sinner, et al.
Circ 2014; 130:1225-1235
Age-Specific Incidence, Outcome, Cost, and Projected Future Burden of Atrial Fibrillation–Related Embolic Vascular Events: A Population-Based Study.
G Yiin, et al.
Circ 2014; 130:1236-1244
Circulating Omega-6 Polyunsaturated Fatty Acids and Total and Cause-Specific Mortality: The Cardiovascular Health Study.
J Wu, et al.
Circ 2014; 130:1245-1253
Meta-Analysis on Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography.
A Ukaigwe, et al.
AJC 2014; 114:1295-1302
Meta-Analysis of Randomized Trials Comparing the Effectiveness of Different Strategies for the Treatment of Drug-Eluting Stent Restenosis.
R Piccolo, et al.
AJC 2014; 114:1339-1346
Three-Year Patient-Related and Stent-Related Outcomes of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice (From the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
J Lee, et al.
AJC 2014; 114:1329-1338
Prognostic Implications of Creatine Kinase–MB Measurements in ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention.
A Bagai, et al.
AHJ 2014; 168:503-511



Poll Archives
DKCRUSH-VI trial
Shao-Liang Chen, MD, et al.
| Watch CardioTube Interview
PARTNER Trial
Samir R. Kapadia, MD
| Watch CardioTube Interview
RIBS IV Clinical Trial
Fernando Alfonso MD, PhD
| Watch CardioTube Interview
VELOCITY Trial
Gregg W. Stone, MD
| Watch CardioTube Interview
EXCITE ISR Trial
Eric J. Dippel, MD
| Watch CardioTube Interview
Renal artery denervation with a new simultaneous multi-electrode catheter for treatment of resistant hypertension: 12-month update from the first-in-man study
Robert Whitbourn, MD, et al.
SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: Post Hoc Analyses of 12-Month Results
Deepak L. Bhatt, MD, MPH, et al.
SYMPLICITY HTN-3: Analysis of the African-American and Non-African American Populations
John M. Flack, MD, et al.
Preclinical Insights Into the Optimal Ablation Location for Renal Denervation Procedures
Robert J. Melder, ScD
Two-Year Clinical Results of OPTIMIZE Trial
Fausto Feres, MD, PhD
Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Compared with Surgical Aortic Valve Replacement in High Risk Patients
Matthew R. Reynolds, MD
Multi-Vessel Versus Single-Vessel Treatment with Resolute Zotarolimus Eluting Stent in the RESOLUTE Global Clinical Program
Ganesh Manoharan, MD
Percutaneous Coronary Intervention of Small Vessels in the RESOLUTE Global Clinical Program: The Impact of Diabetes Mellitus
Milan Chag, MD
Percutaneous Coronary Intervention of Very Small Vessels in the RESOLUTE Global Clinical Program
Antonio Serra, MD
ABSORB II Trial
Patrick W. Serruys, MD
Randomized CTO-IVUS study
Yangsoo Jang, MD, PhD
ISAR-CLOSURE Randomized Trial
Stefanie Schupke , MD, et al.
OCT STEMI Study
P. Cervinka, MD, et al.
CLEAN-TAVI Trial
Axel Linke, MD , et al.
Two-Year Results From the CoreValve US Pivotal Trial
Steven J. Yakubov, MD
ISAR-TRIPLE Trial
Katrin A. Fiedler, MD, et al.
SECURITY Randomized Clinical Trial
Antonio Colombo, MD
BRIGHT Trial
Yaling Han, MD
TRANSLATE-ACS Trial
TRANSLATE-ACS Investigators
The IN.PACT Global Clinical Study
Gary M. Ansel, MD
1-year Results from the IN.PACT SFA II Trial
Adam C . Salisbury, MD, et al.
EVERBIO II Trial
Serban Puricel, MD, et al.
I-LOVE-IT 2 Trial
Bo Xu, MD

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
BIOFLOW-II Trial
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD


ACS & AMI
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2013 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login


Copyright © 2014, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb